121 related articles for article (PubMed ID: 35469982)
1.
Qi Z; Pei P; Zhang Y; Chen H; Yang S; Liu T; Zhang Y; Yang K
J Control Release; 2022 Jun; 346():240-249. PubMed ID: 35469982
[TBL] [Abstract][Full Text] [Related]
2. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
3. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
Wen X; Zeng X; Cheng X; Zeng X; Liu J; Zhang Y; Li Y; Chen H; Huang J; Guo Z; Chen X; Zhang X
Mol Pharm; 2022 Oct; 19(10):3612-3622. PubMed ID: 35652897
[TBL] [Abstract][Full Text] [Related]
4. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
5. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
Xin B; Yang M; Wu P; Du L; Deng X; Hui E; Feng GS
Hepatology; 2022 Sep; 76(3):630-645. PubMed ID: 34860431
[TBL] [Abstract][Full Text] [Related]
7. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic Immunomodulatory Functions of Radioactive Inactivated Bacterial Vectors for Enhanced Cancer Radio-immunotherapy.
Pei P; Zhang Y; Jiang Y; Shen W; Chen H; Yang S; Zhang Y; Yi X; Yang K
ACS Nano; 2022 Jul; 16(7):11325-11337. PubMed ID: 35819107
[TBL] [Abstract][Full Text] [Related]
10. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
Ramamurthy C; Wheeler KM; Trecarten S; Hassouneh Z; Ji N; Lee Y; Svatek RS; Mukherjee N
J Cancer Immunol (Wilmington); 2024; 6(1):29-39. PubMed ID: 38784962
[TBL] [Abstract][Full Text] [Related]
11. Synergism of
Wen X; Zeng X; Liu J; Zhang Y; Shi C; Wu X; Zhuang R; Chen X; Zhang X; Guo Z
Bioconjug Chem; 2022 Nov; 33(11):2170-2179. PubMed ID: 36256849
[TBL] [Abstract][Full Text] [Related]
12. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.
Zheng J; Huang J; Zhang L; Wang M; Xu L; Dou X; Leng X; Fang M; Sun Y; Wang Z
Biomater Res; 2023 Feb; 27(1):9. PubMed ID: 36759928
[TBL] [Abstract][Full Text] [Related]
13. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.
Garcia MG; Deng Y; Murray C; Reyes RM; Padron A; Bai H; Kancharla A; Gupta H; Shen-Orr S; Curiel TJ
Aging Cancer; 2022 Mar; 3(1):68-83. PubMed ID: 36876140
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
16. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
[TBL] [Abstract][Full Text] [Related]
17. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
Shi X; Shu L; Wang M; Yao J; Yao Q; Bian S; Chen X; Wan J; Zhang F; Zheng S; Wang H
Adv Sci (Weinh); 2023 May; 10(15):e2204890. PubMed ID: 37017572
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
Chandramohan V; Bao X; Yu X; Parker S; McDowall C; Yu YR; Healy P; Desjardins A; Gunn MD; Gromeier M; Nair SK; Pastan IH; Bigner DD
J Immunother Cancer; 2019 May; 7(1):142. PubMed ID: 31142380
[TBL] [Abstract][Full Text] [Related]
19. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.
Chen J; Yang J; Wang W; Guo D; Zhang C; Wang S; Lu X; Huang X; Wang P; Zhang G; Zhang J; Wang J; Cai Z
Cell Mol Immunol; 2022 Nov; 19(11):1290-1301. PubMed ID: 36220994
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model.
Lim S; Park JH; Chang H
Investig Clin Urol; 2023 Jan; 64(1):74-81. PubMed ID: 36629068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]